Compare NUVB & NAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVB | NAC |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | France |
| Employees | 298 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 1998 |
| Metric | NUVB | NAC |
|---|---|---|
| Price | $4.76 | $11.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.38 | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 573.1K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $203.82 | N/A |
| Revenue Next Year | $58.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $10.69 |
| 52 Week High | $9.75 | $12.25 |
| Indicator | NUVB | NAC |
|---|---|---|
| Relative Strength Index (RSI) | 50.85 | 60.94 |
| Support Level | $4.06 | $11.78 |
| Resistance Level | $5.42 | $12.01 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 54.70 | 85.45 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.